Cimetidine
General
- Type: H2 blocker
- Dosage Forms: 200, 300, 400, 800mg
- Common Trade Names: Tagamet HB 200
Adult Dosing
Duodenal Ulcer, Active: 800mg PO QHS x 4-8 weeks
Duodenal Ulcer, Maintenance: 400mg PO QHS
Gastric Ulcer, active benign: 800mg PO QHS x 6 weeks
H. Pylori Infection: 400mg PO BID x 10-28 days
Pediatric Dosing
GERD/PUD:
*Neonates: 5- 10mg/kg/day PO divided q8-12h *Infants: 10-20mg/kg/day PO divided q8-12h *Children: 20-40mg/kg/day PO divided q6H
Special Populations
- Pregnancy Rating: B (animal studies show no risk for adverse fetal effects, human fetal harm possible but unlikely)
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCL 10-50: decrease dose 50%, CrCl <10, decrease dose 75%
- Pediatric: CrCl 20-40, decrease dose 25% or give q8h, CrCL <20: decrease dose 50%
- Hepatic Dosing
- Adult: Not Defined
- Pediatric not defined
Contraindications
- Allergy to class/drug
- caution if renal impairment - caution if hepatic impairment - caution in elderly patients - caution if chronic pulmonary disease - caution if DM - caution if immunocompromised
Adverse Reactions
Serious
- neutropenia - thrombocytopenia - agranulocytosis - aplastic anemia - pneumonia -depression -psychosis -hallucinations -pancreatitis -interstital nephritis -bradycardia -tachycardia -AV block - skin reaction
Common
-headche -diarrhea -dizziness -gynecomastia -nausea -vomiting -confusion -agitation -drowsiness -rash -ALT,AST elevation
Pharmacology
- Half-life: 2H
- Metabolism: Liver; CYP450, 1A2, 2C19, 2D6 Inhibitor
- Excretion: urine
- Mechanism of Action: Histamine H2 Receptor blocker
